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INTRODUCTION
In Washington v. Glucksberg, 1 the Supreme Court recognized that a "good physician is
not just a mechanic of the human body whose services have no bearing on a person's
moral choices, but one who does more than treat symptoms, one who ministers to the
patient." 2 The doctor-patient relationship is a highly personal one where doctors, by
virtue of their relationship with a patient and knowledge of his medical condition, can
best advise the patient. 3 This relationship has traditionally been treated as a sacrosanct
relationship with fiduciary duties. 4 The duties imposed on doctors involve fully
informing the patient about treatment options and maintaining the established standard
of care. 5 Traditional legal principles, such as medical malpractice and informed consent,
help ensure that doctors deliver the best possible care. 6
It is especially important to protect the doctor-patient relationship when dealing with a

life-threatening condition such as Opioid Use Disorder ("OUD"). 7 Unfortunately, the
most effective treatment for OUD, the use ofbuprenorphine, is currently also one of the
most restricted treatments in the field of medicine. 8 The treatment of OUD is the only
area of medicine in which a doctor's ability to prescribe a certain drug is limited by the
number of patients that the doctor treats. 9 This restriction is especially egregious since
buprenorphine is a potentially lifesaving medication during a nationwide epidemic. 10

1

521 U.S. 702 (1997).

2

Id. at 779 (Souter, J., concurring) (citing Roe v. Wade, 410 U.S. 113, 153 (1973)).

3 Desimini v. Bristol Hosp., Inc., 927 A.2d 1004, 1007 (Conn. Super. Ct. 2007) (citing Sherwood
v. Danbury Hospital, 896 A.2d 777 (Conn. 2006)); Vitanza v. Upjohn Co., 778 A.2d 829 (Conn.
2001 )).

4

Wohlgemuth v. Meyer, 293 P2d 816, 820 (Cal. Dist. Ct. App. 1956).

5

Paden v: Rudd, 669 S.E.2d 548, 550 (Ga. CL App. 2008).

6

For an explanation of the progression of medical malpractice standards see Peter Moffett &
Gregory Moore, The Standard of Care: Legal History
The Bad and Good News,
12 WEST. J. EMERGENCY MED. 109, 109-112 (2011). Even with the current "minimally competent
physician" standard, described by Moffet and Moore, malpractice still serves as a measuring stick
for maintaining a certain quality of care. Id at 110-12; See also Michael C. Barnes & Daniel C.
McClughen, Warm Hando.!Js: The Duty
Departments
in Reducing the Risk ofSubsequent Drug Overdoses, 48 U. MEM. L. REv. 1099, 1130-42 (2018)
(explaining potential medical malpractice liability for hospitals who release patients without a wam1
handoff policy).
7

See
Joshua W. Elder et. al., Optimal Implementation ofPrescription Drug i\1onitoring
Programs in the Emergency Department, 19 WEST. J. EMERGENCY MED. 387, 387 (2018) (describing
OUD as the "most significant modern-day, public health crisis").
8

See

notes 51-5 8 and accompanying text.

9

30 100 Patient Limit, NAT'L ALLIANCE OF ADvoc. FOR BuPRENORPHINE TREATMENT, https://www.
naabt.org/30_patient_limit.cfm [hereinafter 30 100 Patient Limit].
10
See
and Buprenorphine: Opioid Agonist Substitution Tapers, PROVIDERS
CLINICAL SUPPORT SYS., (Dec. 6, 2017), https://pcssnow.org/resource/methadone-buprenorphineopioid-agonist-substitution-tapers (describing how blocking withdrawal symptoms and reducing
cravings reduces the risk of relapse).
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Another threat to the doctor-patient relationship is unfair business practices. Market
leading businesses, which range from addiction recovery centers to behavioral healthcare
hospitals, present outdated abstinence treatment methods as superior to medicationassisted treatment. 11 Twelve-step abstinence-based treatment programs reject the use
ofbuprenorphine; therefore, these businesses do not provide the necessary institutional
support required for the growth of buprenorphine-medication assisted treatment
("B-MAT").I 2 However, outcome-based research clearly shows that medicationassisted treatment ("MAT") with medicines like buprenorphine is dramatically superior
to abstinence. 13 Alex Azar, Secretary of the U.S. Department of Health and Human
Services (HHS), has stated that not offering MAT is like "trying to treat an infection
without antibiotics."I 4
One of the most prominent threats to the doctor-OUD patient relationship is patient
discrimination; doctors often see OUD patients as "moral failures" rather than people
affected by a chronic condition. Is Further, Congress continues to display bias by
imposing limits on buprenorphine prescribing, I6 and, in the past, doctors were even
disciplined for prescribing opiates for maintenance. I7 However, the focus of this Article
is not to discuss whether a bias exists toward OUD patients; instead, it proposes that
informed consent has the potential to serve as more than a 'checkbox' to avoid litigation,
and genuinely enhance the doctor-OUD patient relationship. Regardless of the existing
bias, OUD patients should have the right to self-determination. Is
Given its life-and-death ramifications, OUD treatment provides a valuable case study
of the benefits of informed consent on patient treatment.I 9 According to a 2019 study,
opioid deaths are expected to skyrocket by 2025, and researchers have identified the

11

See e.g.,

notes 99-101 and accompanying text

12

See e.g., Katrine Jo Andersen & Cecilie Maria Kallestrup,
· How the 12
Program and Its
the
Crisis, NEw REPUBLIC (June
27, 2018),
(describing a Louisville, Kentuckj
native's experience feeling like a "fraud" in a 12-step program because he was also prescribed
suboxone ).
13
See Alex M. Azar,
to National Governors Association (Feb. 24, 2018)
(transcript available at https://W>vwhhs.gov/about/leadership/secretary/speeches/2018-speeches/
that MAT can "reduce[] future
chances of a fatal overdose
14 Id

See Robert Heimer et aL, ,.,,,.,,vn,,,,m 1vw'°""'~""'mu·ms
Use Disorders in the United
and Public Health Responses, 69 CLINICAL INFECTIOUS DrsEASES 546,
548 (2018)
the misconception ofaddicts as moral failures).
15

16

See

notes 52-57 and

text

17

See Webb v. United States, 249 US. 96, 99 (1919) (holding that a physician cannot prescribe
opiates to a person
from addiction).
18
See Jenny Lindberg et aL, Temporising
Ernrcs 161, 161 (2019) (explaining that self-detennination, in the '1rn'.trnr-n:1t1
context, means that it is the
who should decide which treatment option to pursue).
19

Qiushi Chen et aL, Prevention
Overdose Deaths in
the United States, JAMA NETWORK 1, 9 (2019), https://jamanetworkcom/journals/jamanetworkopen/
fullarticle/2723405.
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need for a "multipronged approach" that identifies those with OUD and improves their
access to medications for treatment. 20 This Article proposes that an improved informed
consent structure, tailored to the provider-ODD patient relationship, can play a role
in narrowing the treatment gap by destigmatizing those with OUD, placing them in a
decision-making position, and showing that understanding and accessing MAT does not
have to be so difficult. 21
While other Articles have discussed potential factors that may contribute to the limited
utilization of MAT with buprenorphine, this Article will specifically analyze the unique
legal factors involved. First, in Section I, this Article will review the history of drug
regulation, and explain how legislation has adapted in response to the dramatic changes
in opioid use that have taken place, particularly over the past two decades. 22 Next, in
Section II, this Article will present a novel perspective on how fully informing patients
of their available treatment options will create a dynamic shift away from unfair business
practices that restrain the doctor-OUD patient relationship. 23 Next, Section III proposes
a tailored list of best practices, specific to the OUD treatment setting, that doctors should
implement when securing informed consent. 24 Finally, this Article suggests that the
legal profession, legislators, and government agencies can play an important role in
making lifesaving treatment more readily available.

I. BACKGROUND
A. History of Drug Regulation

The United States has a long history of drug regulation designed to prevent opioid
abuse. 25 In the early l 900's, legislation involving opioids started to become progressively
more restrictive. 26 Regulation began with ingredient disclosure (1906 Pure Food and
Drug Act) and truthful labeling (1912 Sherley Amendmentto the Pure Food and Drug
Act) requirements for products containing opioids. 27 Next, opioid distribution itself was
limited by the Harrison Narcotics Tax Act of 1914, 28 which allowed for the distribution
of opiates by a physician only "in the course of his professional practice."29 Because
20

Levy's belief that the idea that a person is
that the "benefits of the medications
Part L
Part II.
Part Ht
amrlm.en1"1 u·~'+11Li<mvm11oau

26

in the United States, U.S. FooD &
[hereinafter Milestones].

DRUG ADMIN., hm,0·1m""'"

Pure Food and Drug Act of 1906, Pub. L No. 59-384, 34 Stat 768 (1906).

Id; Pure FoodandDrugActof 1906, Pub. L No. 62-301, 37 Stat 416, 417 (1912);Milestones,
supra note 25.
28

29

See Harrison Narcotics Tax Act, Pub. L No. 63-223, 38 Stat 785 (1914)
for addiction treatment is "so
a ,.,,.,,...,Pro""'
Id;
v. United States, 271 US. 104, 105 (1926).
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addiction was considered a moral failing and not a disease, doctors were not allowed
to prescribe opiates for addiction treatment. 30 Twelve-step abstinence programs were
established as a result of this emphasis on addiction as a moral failing and the resulting
limitations on medical treatment. 31 Alcohol addiction was the first disorder addressed
when Alcoholics Anonymous was formed (AA) in 1935. 32 Next, in 1953, Narcotics
Anonymous (NA) was built on the same twelve-step principles. 33
While the number of abstinence programs continued to increase, regulation of opioids
also continued with the passage of the Controlled Substances Act (CSA), 34 which was
passed as part of the Comprehensive Drug Abuse Prevention and Control Act of 1970. 35
The CSA created five controlled drug classifications (schedules 1-V) and a "closed
system" in which anyone authorized by the Drug Enforcement Agency (DEA) to handle
controlled substances had to register. 36
Finally, in 1974, physicians could once again use opioids to treat OUD patients. 37
Methadone, a long-acting opioid, proved effective in controlling withdrawal symptoms,
and in 1972 the Food and Drug Administration (FDA) approved its use for the treatment
of opioid addiction. 38 The Narcotic Addict Treatment Act of 1974 allowed federally
licensed programs ("methadone clinics"), but not individual physicians, to dispense
medication for "detoxification" or "maintenance" purposes. 39 During this period,
researchers were also working on developing buprenorphine. 40 Buprenorphine was
unique because it had a limited maximum or "ceiling" effect and a long half-life. 41 Such

30

Webb v. United States, 249 US. 96, 99-100 (1919).

31

See

notes 32-33 and accompanying text

32

Over 80 Years
ALCOHOLICS ANONYMOUS, https:/hvww.aa.org/pages/enUS/aa-timeline;
see also Historical Data: The Birth
and Its Growth in the US/Canada, ALCOHOLICS
ANONYMOUS, https://www.aa.org/pages/en_US/historical-data-the-birth-of-aa-and-its-growth-in-theuscanada
that "AA. had its beginnings in 1935 at Akron, Ohio, as the outcome of a meeting
between Bill W, a New York stockbroker, and Dr. Bob S., an Akron surgeon."). In 1939 the program
"published its basic textbook,
Id.
33
34

About NA, NARCOTICS ANONYMOUS, https://www.na.org/aboutus/?ID=PR-index.
21 US.C. § 812 et seq. (1970).

35

Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L No. 91-513, 84 Stat
1236 (1970).
36 See 21 US.C. § 812; Diversion Control Division, Resources, US. DEPT. OF JusnCE, https://
wvvw.deadiversion. usdoj .gov/21 cfr/cfr/2108cfrt.htm (explaining the five schedules and process for
registration).
37

Narcotic Addict Treatment Act of 1974, Pub. L No. 93-281, 88 Stat 124 (1974).

38

Rebecca L Haffajee et al.,
to Address Provider
Treatment, 54 AM. l PREVENTATIVE MED. S230, S231 (2018).

Barriers to

jjuon:norv~1me
39

§ 303, 88 Stat at 124; A History of Opiate Laws in the United States, NAT'LALL. OF ADVOCATES
FOR BuPRENORPHINE TREATMENT, http://W\v\lv.naabt.org/laws.cfm (last visited Sept 16, 2019).

40

Nancy D. Campbell & Anne M. Lovell, The History
Development
1248 ANNALS NY AcAD. ScL 124, 131-37 (2012).

as an

Addiction
41

Id; see supra note 10 (stating that buprenorphine's "ceiling effect" makes it safer than other

opioids).
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features made buprenorphine ideal for the treatment of withdrawal because it requires
only a single daily dose and reduces the risks associated with methadone. 42
Buprenorphine has proven to be effective. For example, in 1995, France (where
primary care doctors are the primary prescribers of buprenorphine and may prescribe
it without any special license or training) first allowed doctors to prescribe the drug
for the treatment of OUD, and within four years the number of deaths caused by
overdose declined by seventy-nine percent. 43 In the United States, the medical use of
opioids significantly increased in the 1990's when doctors began to treat pain more
aggressively. 44 In the mid-1990's, the American Pain Society proposed the recognition
of pain monitoring as a "fifth vital sign," and in 2000, hospital systems such as the
Veterans Health Administration (VA) began to recognize it as such. 45 Subsequently, in
2001, the Joint Commission46 accepted such monitoring as one of its standards. 47 Along
with an increase in opioid prescriptions, there was a parallel increase in the number of
diagnoses ofOUD. 48 By this time, the abstinence model was a prominent treatment for
the growing number ofOUD patients. 49
The United States subsequently established stricter regulations concerning the use
of buprenorphine for OUD treatment, and relaxation of these regulations has been
slow. 50 For instance, the Drug Addiction Treatment Act of 2000 (DATA 2000) allowed

42

Methadone does not have a ceiling effect like buprenorphine does, so as the dose of methadone
increases so do the risks of side effects such as impairment, respiratory depression, and even death.
See Haffajee, supra note 38, at S232; Buprenorphine, SuBSTANCE ABUSE AND MENTAL HEALTH SERVS.
ADMIN., https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine (last
visited Nov. 2, 2019).
43

Marc Amiacombe et aL, French Field Experience with Buprenorphine, 13 AM. J ADDICTIONS.
Sl7, S17, S19, S25 (2004).

44

Andrew Rosenblum et aL, Opioids and the Treatment of Chronic Pain: Controversies, Current
Status, and Future Directions, 16 EXPERIMENTAL AND CLINICAL PsvcHOPHARMACOLOGY 405, 406
(2008).

45

See Pain as the 5th Vital Sign Toolkit, DEPT. OF VETERANS AFF., https://www.va.gov/
PAINMANAGEMENT/docs/Pain_As_the_5th_Vital_Sign_Toolkitpdf (stating that "the phrase
'pain as the 5th vital sign' was initially promoted by the American Pain Society to elevate awareness
of pain treatment among healthcare professionals.").

46

See About the Joint Commission, JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE 0RG.,
https://www.jointcommission.org/about_us/about_the_joint_commission_main.aspx [hereinafter
JOINT COMMISSION]. The Joint Commission is an independent, not-for-profit organization that
accredits and certifies over 22,000 health care organizations and programs throughout the United
States for quality and meeting specific performance standards. Id
47

See The Joint Commissions Pain Standards: Origins and Evolution 1, 2, JOINT COMMISSION,
https://vv,,rwjointcommission.org/assets/1/6/Pain_Std_History_Web_Version_OS 122017 .pdf
(explaining the Joint Commission's 2001 introduction of standards for organizations to provide
better care to patients in pain).
48

See Paige M. Smith, Implementing Medicaid Health Homes to Provide Medication Assisted
Treatment to Opioid Dependent Medicaid Beneficiaries, 106 Kv. L REv. 112, 112 (2017)
(describing overdoses and OUD as an "unanticipated consequence" increased prescribing).

49

See Andersen, supra note 12 (describing detox wards, in which patients addicted to opioids stay
while they experience vvithdrawal symptoms from quitting opioids "cold turkey").

so See generally infra notes 51-58 and accompanying text
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physicians who met certain qualifications and conditions to treat OUD patients with
schedule III, IV, and V medications. 51 Since buprenorphine is the only Schedule III-V
medication approved by the FDA for the treatment of OUD, DATA 2000 exclusively
applies to its use for the treatment of OUD. 52 Under DATA 2000, physicians were
capped at a thirty patient limit, marking the first time that doctors were limited to a
certain number of prescriptions they are allowed to prescribe. 53 The 2006 Office of
National Drug Control Policy Reauthorization Act included legislation that advocated
for the increase of patient limits from thirty to one hundred patients after one year of
practice. 54 Ten years later, an HHS regulation allowed qualified physicians to increase
their patient limit to 275 patients, 55 and the Comprehensive Addiction Recovery Act of
2016 ("CARA") allowed "qualified practitioners,"56 including nurse practitioners and
physician assistants, to treat up to thirty patients during their first year and one hundred
patients after the first year. 57 Then, in 2018, the Substance Use-Disorder Prevention That
Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities
Act expanded the group of"qualifying other practitioner[ s]"who could provide B-MAT
to include "clinical nurse specialists, certified registered nurse anesthetists, and certified
nurse midwives" for a five year period in response to the epidemic. 58
51

Drug Addiction Treatment Act of 2000, Pub. L. No. 106-310, §3502, 114 Stat. 123-25
(2000); Drug Scheduling, U.S. DRUG ENFORCEMENT ADMIN., https://www.dea.gov/drug-scheduling
[hereinafter Drug Scheduling] (explaining that the Drug Enforcement Administration classifies
Schedule HI drugs as having moderate to low potential for physical and psychological dependence,
Schedule IV drugs as having a low potential for abuse and risk of dependence, and Schedule V
drugs as having a lower potential for abuse than Schedule IV drugs and containing limited quantities
of certain narcotics).
52

Drug Scheduling, supra note 51; 30 JOO Patient Limit, supra note 9. Buprenorphine is a
schedule UI drug, while Methadone is a schedule H drug. Naltrexone is not scheduled. Drug
Scheduling, supra note 51.
53

See 30 100 Patient Limit, supra note 9 (stating that "no other medications have such restrictions,
including prescription drugs people get addicted to and die from").
54

Office of National Drug Control Policy Reauthorization Act, Pub. L. No. 109-469 (formerly
H.R.6344), Title XI, § 1102 (2006).

55

Medication Assisted Treatment for Opioid Use Disorders, 42 C.F.R. §8.610 2016.

56

See Comprehensive Addiction and Recovery Act of 2016, Pub. L. No. 114-198, 130 Stat.
695, 720-23 (2016). As defined in the Comprehensive Addiction and Recovery Act ("CARA"),
a qualifying physician must be licensed under state law and satisfy one or more of the following
requirements: hold a subspecialty board certification in addiction psychiatry from the American
Board of Medical Specialties, hold an addiction certification from the American Society of
Addiction Medicine, or a subspecialty board certification in addiction medicine from the American
Osteopathic Association; complete a minimum of eight hours of training in a specific location;
must had participated as an investigator in a clinical trial leading to approval of a schedule III, Iv,
or V narcotic; have additional training that either the state licensing board or Secretary of Health
and Human Services deems sufficient. Id. Further, a qualifying practitioner, which includes nurse
practitioners and physician's assistants must hold licensure under state law to prescribe schedule HI,
rv; and V pain medications, complete a minimum 24 hours of training as outlined by the Act, and
work with or under the supervision of a qualifying practitioner. Id.
s1 Id.
58

Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients
and Communities Act, Pub. L. No. 115-271, 132 Stat. 3894(2018); Resources: Buprenorphine
Waiver Management, AM. Soc'y OF ADDICTION MED., https://www.asam.org/resources/practice-
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B. Statistics

Since the rates of opioid prescriptions began to increase in the 1990's, the number of
overdoses and deaths from synthetic opioid use has also steadily increased. 59 Between
1999 and 2016, the number of deaths involving prescription opioids increased
fivefold%nearly 64,000 Americans overdosed in the latter year. 60 In 2019, opioid
overdoses surpassed car accidents as a leading cause of preventable deaths. 61 According
to data from the Substance Abuse and Mental Health Services Administration
(SAMHSA), approximately 2.1 million Americans over the age of twelve are believed
to have an opioid use disorder. 62
From July 2016 to September 2017, opioid overdoses increased thirty percent m
fifty-two areas across forty-five states, which led HHS to declare opioid addiction a
public health emergency in 2017. 63 Additionally, the Centers for Disease Control and
Prevention (CDC) estimates that nearly every eight minutes, an American dies of a drug
overdose. 64 Further, opioid misuse has resulted in many life-threatening infections65

resources/buprenorphine-waiver-management#bupauthority (last visited Nov. 2, 2019) [hereinafter
ASAM]; Buprenorphine Patient Limits: History and Overview NAT'L Ass'N OF STATE ALCOHOL AND
DRUG ABUSE DIRECTORS, https://nasadad.org/wp-content/uploads/2019/0 l/Buprenorphine-PatientLimits-1.pdf (last visited Nov. 2, 2019).
59

See Christopher Ingraham, CDC Releases Grim New Opioid Overdose: 'We 're Talking About
More Than an Exponential Increase, 'WASH. PosT, (Dec. 21, 2017), https://www.washingtonpost
com/news/wonk/wp/2017 /12/21/cdc-releases-grim-new-opioid-overdose-figures-were-talkingabout-more-than-an-exponential-increase/ (presenting statistics showing a 2016 surge in deaths from
fentanyl and other synthetic opiates).
60

Opioid Overuse: Overview, CTR. FOR DISEASE CONTROL AND PREVENTION, https://www.cdc.gov/
drug overdose/data/prescribing/overview.html [hereinafter CDC].
61

Tauren Dyson, Opioid Overdoses Top Jvlotor Vehicle Crashes as Cause ofPreventable
Death, UPI: HEALTH NEws, (Jan. 14, 2019), https://www.upi.com/Health_News/2019/0l/14/
Opioid-overdoses-top-motor-vehicle-crashes-as-cause-of-preventable-death/6631547 4 7 4852/?st_
rec=4591547584097.
62
Rebecca Ahrnsbrak et al., Key Substance Use and Mental Health Indicators in the United States:
Results from the 2016 National Survey on Drug Use and Health, SuBSTANCE ABUSE AND MENTAL
HEALrH SERVICES AD MIN. (Sept 2017), https://www.samhsa.gov/data/sites/default/files/NSDlJHFFRl-2016/NSDUH-FFRl-2016.htm [hereinafter SAMHSA].
63

See Opioid Overdoses Treated in Emergency Departments: ldenti.fY Opportunities for Action,

CDC, https://www.cdc.gov/vitalsigns/opioid-overdoses/index.html (stating that this increase was
even more drastic in some larger cities and in the Midwestern region of the country); HHS Acting
Secretary Declares Public Health Emergency to Address National Opioid Crisis, DEP'T OF HEALTH
& HuMAN SERV. (Oct 26, 2017), https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretarydeclares-public-health-emergency-address-national-opioid-crisis.html [hereinafter HHS].
64

Statement of Commissioner Ro hit Chopra, FTC, (July 11, 2019), https://www.ftc.gov/system/
files/documents/public_statements/1534673/chopra_-_reckitt_statement_7-11-19 .pdf. See also
National Kickoff Call: OPIS-S2 (Opioid Prevention in States-Surge Support) via the Cooperative
Agreement for Emergency Response, CTR. FOR DISEASE CONTROL: NAT'L CTR. FOR INJURY PREVENTION
AND CONTROL (Sept.12, 2018), https://www.cdc.gov/cpr/readiness/OO_docs/Opioid_Crisis_CoAg_
National_Call_Slide_Deck_September_13_Final-a_Sept_l8.pdf.
65

Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs: A
Treatment Improvement Protocol (TIP 43), ASAM, 1, 163-64, https://www.asam.org/docs/
advocacy/samhsa_tip43 _matforopioidaddiction.pdf?sfvrsn=O (last visited Nov. 2, 2019).
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and over one thousand opioid-related emergency room visits per day. 66 Lastly, opioid
misuse also carries an astronomical economic burden; the CDC estimates that its
costs, including health care, lost productivity, addiction treatment, and criminal justice
involvement, exceed $78.5 billion per year in the United States. 67
The number of patients seeking treatment also continues to increase. 68 For example,
the number of treatment facility admissions for opioid use increased fifty-eight percent
between 2005 and 2015. 69 Unfortunately, the majority of those suffering from OUD are
not receiving effective treatment. 70 According to a 2016 report by the Surgeon General,
only ten percent of people with a drug use disorder received specialty treatment due
to a lack of access to care. 71 Even when patients receive treatment, data suggests that
less than half of treatment facilities offer opioid addiction medications. 72 SAMHSA
data through 2015 showed that only 41.2 percent of more than 12,000 drug addiction
treatment facilities in the United States provided at least one kind of medication for
the treatment of opioid addiction. 73 Likewise, only 6.1 percent of treatment facilities
offered all three medications approved by the FDA for OUD treatment (buprenorphine,
methadone, and naltrexone ). 74 This data suggests that the abstinence model continues to
dominate OUD treatment. 75

66

CSC Launches Campaign to Help States Fight Prescription Opioid Epidemic, CDC (Sept. 25,
2017), https://www.cdc.gov/media/releases/2017 /p0925-rx-awareness-campaigns.html.
67

Rita Milios, Opioid Abuse: A Crisis and a Challenge, RECOVERY.ORG: AM. ADDICTION CTR.
RESOURCE (Oct.2, 2017), https://www.recovery.org/pro/articles/opioid-abuse-a-crisis-and-achallenge/; See also Curtis Florence et al., The Economic Burden ofPrescription Opioid Overdose,
Abuse,
in ihe United States, 2013, 54 MED. CARE. 899, 901-06 (2016).
68 Treatment Episode Data Set (TEDS) 2005 2015, SAMHSA, https://wwwdasis.samhsa.gov/
dasis2/teds_pubs/2015 _teds_rpt_natl.pdf (last visited Sept 16, 2019) [hereinafter TEDS].

69

Id; Dem1is McCarty et al., Treatment and Prevention
39 ANNU. REv. PuB. HEALTH 525, 531 (2018).

Use Disorder:

70

See e.g., Executive
Surgeon General :S Report on Alcohol, Drugs, and Health,
SuRGEON GEN., https://addiction.smgeongeneral.gov/executive-smmnary (last visited Sept. l 6, 2019)
(stating that "only about 10 percent of people with a substance use disorder receive any type of
specialty treatment").
71 Id
72

TEDS, supra note 68.

73

Austin Jones et al., Where
Modes
Treatment Are Available,
HEALTHAFF. BLOG (Jan. 9, 2018), https://ww\:v.healthaffairs.org/do/10.1377/hblog20180104.835958/
full; see Ramin Mojtabai et al., Medication
Opioid Use Disorders in Substance Use
Treatment Facilities, 38 HEALTH AFF. 14, 17 (Jan. 2019), (stating that in 2016 only thirty-six percent
of medical facilities offered any of the three medications approved by the FDA).
74

Mojtabai, supra note 73, at 17.
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See Andersen, supra note 12 (describing a Louisville, Kentucky native's experience feeling like a
"fraud" in a 12-step program because he was also prescribed suboxone).
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C. Treatment Options

In response to the OUD epidemic, researchers have extensively evaluated the
effectiveness of available treatment methods. 76 Through this research, OUD has come to
be seen as a "chronic medical disease" rather than an ongoing series of moral failures. 77
There are currently three FDA approved medications for OUD: methadone, naltrexone,
and buprenorphine. 78 Each has proven effective, but the three differ in safety, side
effects, ease of use, and risk of diversion. 79 Additionally, the medications differ in who
is authorized to prescribe or dispense them, and how difficult it is for patients to receive
treatment with each medication. 80
Naltrexone blocks the opioid receptors in the brain, but does not provide any relief for
ongoing withdrawal symptoms. 81 Patients must abstain from opioids for at least one
week before starting naltrexone. 82 Since naltrexone is not a controlled substance, it can
be prescribed by any licensed physician. 83 However, if patients stop taking the drug and
start reusing opioids, their risk of a life-threatening overdose increases. 84
Methadone can only be dispensed through licensed opioid treatment programs ("OTP"),
which are extensively regulated. 85 For safety reasons, patients must visit these treatment
centers daily and take the medication under supervision. 86 This treatment regimen often

76
Definition ofAddiction, AM. Soc'y
resomces/definition-of-addiction.

OF

ADDICTION MED. (Aug. 15, 2011), https://www.asam.org/

77

Id. For example, the American Society of Addiction Medicine (ASAM) states that addiction is "a
treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the
environment, and an individual's life experiences. People with addiction use substances or engage
in behaviors that become compulsive and often continue despite harmful consequences. Prevention
efforts and treatment approaches for addiction are generally as successful as those for other chronic
diseases." Id.
78
Nora D. Volkow et al., A1edication-Assisted Therapies3;4Tackling the Opioid-Overdose Epidemic,
370 N. ENGL. J. Mm, 2063, 2064-65 (2014).
79

Id. at 2065; HaidenA. Huskamp et al., Coverage ofi\1edications that Treat Opioid Use Disorder
and Opioidsfor Pain Management in Marketplace Plans, 2017, 56 MED. CARE 505, 506 (2018).
80

Huskamp, supra note 79.

81

Volkow, supra note 78, at 2065.
Id.

82

83
Naltrexone, SAMHSA, https://www.samhsa.gov/medication-assisted-treatment/treatment/
naltrexone (last visited Nov: 17, 2019).

84
Id. (stating that "it is possible that the dosage of opioid that was previously used may have 'lifethreatening' consequences").
85
Huskamp, supra note 79; Oversight of Opioid Treatment Program (OTC) Accrediting Bodies,
SAMHSA, https://www.samhsa.gov/medication-assisted-treatment/legislation-regulationsguidelines/oversight (last visited Oct. 22, 2019) (explaining how SAMHSA obtained administrative
responsibility over the use of opioid medications in maintenance and detoxification of substance
abused disorders).
86
Volkow, supra note 78, at 2065. SAMHSA has administrative responsibility over the use of
opioid medications in maintenance and detoxification treatment of substance use disorders and has
established procedmes for an entity to become an approved accrediting body. See Certification
Opioid Treatment Programs (OTPs), SAMHSA, https://W\,rw.samhsa.gov/medication-assistedtreatment/opioid-treatment-programs.
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creates hardships for patients because it may interfere with their daily schedule, family,
work, and other responsibilities. 87 The required monitoring may also be embarrassing
and stigmatizing to patients. 88
Finally, buprenorphine can be prescribed in an office-based setting, which does not
interfere with patients' work and family schedules but can only be prescribed by
practitioners who receive an authorization from the DEA. 89 Buprenorphine suppresses
symptoms more effectively than methadone, while still allowing for once daily dosing. 90
Currently, the standard of care for the treatment of OUD is extended maintenance on
an opioid agonist. 91 Because the medical profession played a role in the emergence
of the recent opioid epidemic through aggressive management of pain, and because
physicians play a central role in the treatment ofOUD, regulators have focused much of
their efforts on regulating physicians. 92 The regulatory framework governing physicians
prescribing buprenorphine for OUD markedly departs from the typical regulation of
the professional practice of medicine. 93 In the area of OUD treatment, regulations
have limited physician autonomy more than in any other area ofmedicine. 94 Given the
definition of OUD as a chronic medical disease, along with the strong research support
for treatment with medication, preserving the physician-patient relationship model of
care is particularly important. 95
II. ANALYSIS
A. The Current OUD "Treatment Gap"

The National Survey of Substance Abuse Treatment Services (NSSATS) indicates that
in 2016 over one million patients were treated at 15,000 substance abuse treatment
facilities. 96 Today's OUD treatment environments include general hospitals, behavioral
s7 Huskamp, supra note 79.
88

Id.

89

See supra notes 51-5 5 and accompanying text

90

See Volkow, supra note 78, at 2065 (presenting a chart comparing the advantages, disadvantages,
uses, and effects of methadone, buprenorphine, and naltrexone ).
91

Andrew S. Huhn & Kelly E. Dunn, Why Aren
78 J SUBSTANCE ABUSE TREATMENT 1, 2 (2017). Opioid agonists are drugs that activate the opioid
receptors in the brain. What is this
NAT'Li'l.LLIANCE OF ADVOC. FOR
BuPRENORPHlNE TREATMENT, https://wv.w.naabt.org/faq_answers.cfm ?ID=5.
92

See
sarrih,;a. ~:ov;1m(:du;at1on--as:;1sted-treatn1enV kog15;Jatmn-regulatHJns-g1.11d(:Jrn es/spt:cia (describing
limitations placed on physicians
the Controlled Substances Act and the Narcotic Addiction
Treatment Act).
93

See supra notes 52-58 and accompanying text

94

See supra notes 52-58 and

95

See supra notes 77-80 and accompanying text.

text

96
Notably, although buprenorphine is considered the standard of care for OUD, only twenty-seven
percent of the facilities provided that treatment regimen. National
Treatment Services (N-SSAT;.,): 2016 Data on Substance Abuse Treatment Facilities, SAMHSA, at
1-3, 24, https://www.sanilisa.gov/data/sites/default/files/20 l 6_NSSATS. pdf (stating that the survey
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health hospitals, recovery centers, and opioid treatment programs ("OTP"). 97 Two major
legal issues affecting these environments are unfair business practices and a lack of
informed consent. 98
False advertising is a persisting unfair business practice in some facilities. For example,
Richard Taite, the owner of Cliffside Malibu, a "world class luxury drug and alcohol
treatment center," advertises that his center provides an evidence-based model that offers
the "very best [treatment] science has to offer." 99 In Taite's publications in Psychology
Today, he states that using MAT is simply trading one drug for another, and he asserts
that doctors who prescribe medications for OUD are trying to "keep people dependent
on drugs" for financial reasons, claiming that participating in an abstinence in-patient
treatment program for over ninety days is the best opportunity for long-term recovery. 100
Taite also suggests that it is unsafe to leave children with anyone being treated by MAT,
but these statements contradict outcomes-based research and are detrimental to the
provider-ODD patient relationship. 101
Further, many existing facilities deviate from established standards for informed
consent. 102 The treatment of OUD with Office-Based Opioid Treatment ("OBOT") using

smvey, outpatient treatment was offered by 82% of facilities, and 91 % of the patients received that
treatment. Residential treatment was offered by 24% of facilities and received by 1% of patients.
Inpatient was offered by 5% of facilities and received by 1% of patients. Eighty-fom percent of
all facilities had websites that provide information about a facility's substance abuse treatment
programs, and sixty percent of all facilities provided outreach to persons in the community needing
treatment) [hereinafter N-SSATS].
97

Id

98

See generally infra notes 99-103 and accompanying text.

99

See How We Treat, CLIFFSIDE MALIBU, https://www.cliffsidemalibu.com/how-we-treat/ (last
visited Sept 16, 2019). The Cliffside Malibu seeks the best evidence-based counseling, but the
previous attacks on the use of MAT are clear. This Article proposes that in the same way that
those supporting MAT should not say psychosocial counseling should not be used, a supporter
of abstinence-based treatment oversteps when stating that MAT should not be used. The decision
should ultimately lie with the patient
100

Richard Taite, Appropriate Uses for Suboxone and Subutex Therapies, PSYCHOLOGY TODAY (Mar.
18, 2013), https://www.psychologytoday.com/us/blog/ending-addiction-good/201303/appropriateuses-suboxone-and-subutex-therapies (stating that these medications "keep the individual just
high enough not to have to deal with their underlying pain or trauma and maintain some ability
to function in the world."); Richard Taite, The Move Away From Abstinence Based Addiction
Treatment, PSYCHOLOGY TODAY (Jan. 07, 2015), https://www.psychologytoday.com/us/blog/endingaddiction-good/20150 lithe-move-away-abstinence-based-addiction-treatment (asserting that the
doctors and the pharmaceutical industry push these medications solely for financial reasons).
101

Richard Taite, Suboxone and Methadone Maintenance Therapy: As a Father, My Heart Belongs
to My Children, PSYCHOLOGY TODAY (Nov. 3, 2015), https://www.psychologytoday.com/hk/blog/
ending-addiction-good/201511/suboxone-and-methadone-maintenance-therapy?amp; see generally
Lama B. Monico et aL, Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts,
Compatibilities and Patient Outcomes, 57 l SuBSTANCE ABUSE TREATMENT 89, 89-95 (2015)
(explaining the antagonistic effects of abstinence in comparison with MAT).
102

See generally Azar, supra note 13 (stating "[g]iven what we know, and given the scale of this
epidemic, having just one-third of treatment programs offer the most effective intervention for
opioid addiction is simply unacceptable.").
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buprenorphine is effective, but only about a third of facilities offer such treatment. 103
This Article argues that the source of this shortage is multifactorial and can be best
understood by reviewing the effect of these factors on the physician-ODD patient
relationship. While specific solutions have been proposed to address the treatment gap, 104
this Article focuses on legal principles surrounding the doctor-patient relationship. If
these legal principles are used properly in the care of OUD patients, a wider variety of
effective treatment options will be available.
B. The Doctor-OUD Patient Relationship and the Role of Informed Consent

In Cruzan v. Director, Missouri Dept. of Health, 105 the Supreme Court described the
doctrine of informed consent as "the [sacred] right of every individual to the possession
and control of his own person," which ensures that "every human being of adult years
and sound mind has a right to determine what shall be done with his own body." 106 This
right to the "possession and control" of one's own person was first recognized by the
Supreme Court in 1891 in a negligence action against a railroad company that arose
from an injury caused by a falling train bed. 107 In the medical context, failure to obtain
informed consent is viewed as a breach of a professional duty. 108
The decision in Canterbury v. Spence 109 replaced the "professional practice" standard
in medical malpractice cases with the "reasonable person" standard, which led to an
increase in litigation and to an increase in the number of physicians who were willing
to testify against each other in court. 110 In this case, a nineteen-year-old patient sued
his physician after a routine back surgery left his legs permanently paralyzed. 111 Under

103

Id.

104

See, e.g.,
Health: Hub
VERMONT, http://blueprintforhealth.vermont.gov/
about-blueprint/hub-and-spoke (last visited Oct. 22, 2019) (discussing "Hub and
"Vermont's
system of l'v1AT, which supports people in recovery from OUD); Daniel f' Alford, Collaborative
Care
in Primary Care Using
Five-Year Experience,
JAJ'v1A Network (Mar. 14, 2011), https://jamanetwork.com/journals/jamaintemalmedicine/
fullarticle/226781
a program started at Boston Medical Center which used a !hree-stage
model of collaborative care, between nurse care managers and
physicians, to treat
addicted to opioids); See
Treatment, BALTIMORE CITY HEALTH DEP'T, h1tps://heal1h.
baltimorecity.gov/opioid-addiction-treatment (last visited Oct. 22, 2019)
Baltimore
Health Department's use of a combination of MAT, psychosocial support, and wraparound social
services).
105

497 U.S. 261, 269 (1990).

l0 6

Cruzan, 497 U.S. at 269
129-130 (N.Y. 1914)).
to 7

Union Pacific R. Co. v. Botsford, 141 U.S. 250, 251 (1891).

IOS See Paula Walter, The Doctrine
Consent: To
or Not to
, 71 ST. JoHN
L. REv. 543, 558 (1997) (explaining that injuries claimed in lack of consent actions arise from a
breach of his or her duty to adequately inform the patient).
109

464 F.2d 777 (D.C. Cir. 1972).

110

Id. at 780. Sam Roberts, Jerry
Whose
Led to
Consent Laws, is
Dead at 78, NY TIMES (May 16, 2017). https://www.nytimes.com/2017/05/16/us/jerry-canterburymedical-consent-paralysis.html.
111

464 F.2d at 777-80; Roberts, supra note 110.
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Canterbury, "true consent to what happens to one's self is the informed exercise of a
choice, and that entails an opportunity to evaluate knowledgeably the options available
and the risks attendant upon each." 112 After this case, the standard for informed consent
considers what information was "material to the patient's decision," not what the
"medical custom in the community would demand." 113
If applied correctly in the OUD context, the patient-oriented standard of disclosure
expressed in Canterbury requires a physician to discuss the effectiveness of both an
abstinence program and buprenorphine treatment with his patient. 114 The average
patient has little or no medical knowledge, so he typically must rely on his doctor to help
him make the best medical decision. rn This reliance creates obligations for the doctor
associated with "fiducial qualities," which include the "duty to reveal to the patient that
which in his best interests it is important that he should know." 116

A physician should inform a patient not only of the risks involved with the proposed
treatment, but also of any alternatives that might offer greater benefits than the current
treatment. 117 For some patients, B-MAT promises greater results than the abstinence
model of treatment, which "has one of the worst success rates in all of medicine." 118
Therefore, doctors should inform each patient about both the risks of abstinence
treatment and about more effective treatment alternatives such as B-MAT. 119 Using the
reasonable patient standard of informed consent shifts the doctor's focus from playing
the role of a paternalistic provider, controlling the care of an untrustworthy and morally
flawed patient, to a patient-centered approach that respects the patient's autonomy and
his right to self-determination. 120 While OUD patients have become largely accustomed
to being "beaten down" and treated as moral failures, it is vital that these patients are
treated with respect and afforded the opportunity to make decisions. 121
While there is a concern that the average patient will be unable to understand his
condition and treatment options, Canterbury insists that only "the exceptional patient"
cannot gain at least a basic understanding of his condition. 122 While the physician's
required disclosures need not amount to a "medical education," they must inform the

112
113
114

464 F2d at 780.

Id at 786-87.
Id

115

Id at 780.

117

Id at 781.

118

under a
to disclose all risks
an informed medical decision).
885 (1991).
121
122

Heimer, supra note 15, at 548.
464 F.2d at 782 n. 27.
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patient about available alternative therapies, discuss the results that the patient can expect
to achieve, explain the risks that may ensue from a particular treatment, and highlight
the potential consequences of receiving no treatment." 123 Because many OUD patients
are desperate by the time they obtain treatment, a doctor must take extra precautions to
properly inform these patients. 124 Even though many OUD patients are suffering from
severe withdrawal symptoms such as nausea, vomiting, and chills, they are nonetheless
capable of giving informed consent. 125
To establish the ideal doctor-patient relationship, both the doctor and the patient must
understand the context of the patient's condition. 126 For example, there is a significant
difference in appropriate informed consent for the treatment of a disorder that only the
physician can clearly and fully understand, and a condition for which the treatment
options and studies detailing the outcomes are readily available to patients. 127 Fortunately,
OUD treatments fall in the latter category because patients can easily obtain an accurate
comparison of available treatments. 128 While it may be difficult for some patients to
understand certain technical aspects of OUD treatments, such as the makeup of a
medication or how the medication interacts with the body, most patients can understand
the statistical likelihood of success and the steps that each treatment option involves. 129
OUD treatment is both effective and addresses the treatment gap because physicians can
disseminate information about the treatment to the patient. 130 Patients with an existing
doctor-patient relationship can extend their care to include OUD by the same physician in
a familiar environment. 131 Likewise, patients creating a new doctor-patient relationship
can receive treatment by one provider both for their primary care and for their OUD

123

Id.; see also Stinnett v. Price, 446 S.W2d 893 (Tex. App. 1969) (finding that a doctor telling
a patient that a
was more serious than the patient's previous procedure and that the
procedure could cause a stroke was sufficient to
info1med consent).
124
See
464 F2d at 782. These precautions will be addressed through tailored
informed consent requirements in this Article's Resolution.
125
Edmund Henden, Heroin Addiction and
BIOETHICS 395, 395-401 (2013).

Choice: The Case

Consent, 27
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See Susan Dorr Goold & Mack Lipkin, Jr, The
141 GEN. INTERNAL MED. S26, S29 (1999) (stating that physicians
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Id. (stating that informed consent requires the doctor to disclose information necessary for the
to evaluate available
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See e.g., N-SSATS, supra note 96 (comparing information on mechanisms, phases or treatment,
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needs, as long as the provider is qualified to prescribe buprenorphine. 132 Strengthening
these supportive relationships will help overcome patient resistance to treatment.
C. The Role of Hospitals and Treatment Centers in Providing Institutional
Support to Doctors and Information to OUD Patients

A treatment center should ensure that its service delivery is aligned with the best
treatment options for the community and that its providers inform patients of the
alternative treatments available and the risks and benefits of each treatment. 133 As the
court noted in Darling v. Charleston Community Memorial Hospital, 134 the patient
who enters a hospital for treatment expects that the hospital will attempt to cure his
condition, not that its employees will "act on their own responsibility." 135 Similarly, in
Thompson v. Nason Hospital, 136 a case in which a patient recovered against a hospital
because of the hospital employees' negligent acts, the court held that a hospital could be
held liable for corporate liability if it "fails to uphold the proper standard of care owed
[to its] patient." 137 Under Thompson, a hospital has a duty to maintain safe facilities,
employ and retain competent physicians, oversee physicians who practice medicine in
the hospital, and formulate, adopt, and enforce adequate rules. 138
Applying Thompson to the OUD epidemic, facilities that fail to oversee their providers
or to "formulate, adopt, and enforce adequate rules" would be subject to legal
ramifications. 139 Treatment facilities should not be able to ignore current research-backed
best practices. Current prescription policy does not provide resources or institutional
support for providers who want to prescribe MAT. 140 This lack of support for MAT
providers is a noted reason for doctors not seeking to become authorized to provide
MAT, or becoming authorized but not fully utilizing the authorization by prescribing to
fewer patients than permitted. 141
Research shows that educating doctors and patients improves treatment outcomes;
therefore, institutional support for OUD treatment facilities is crucial in improving
patients' chances of successful rehabilitation. 142 Specific training regarding medication
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to "conform to the
includes the
apparent risk").
134

211N.E.2d253

135

Id. at 257.

136

591 A2d 703 (Pa. 1991).

137

Id.

139

Jd.

140

See
Id.

142

ofa
of the

1965).

707.

138

141

App. Ct 1982)
that the
standard of reasonable conduct in

uaua1..,..,,

supra note 38,

S230.

See Amanda l Abraham et al., '-"utm01;wr
70 l SrnD. ALCOHOL & DRUGS 628, 628 (2009)

ueveri•ae11ce.

education have effective

43
Bupren01phine Medication-Assisted Treatment: J7ze Role efInformed Consent

use and observation of that use leads to significant changes in counselors' perceptions
of the effectiveness and acceptability of the medications available for the treatment of
substance use disorders. 143
The authors of Using Medication-Assisted Treatment for Substance Use Disorders:
Evidence of Barriers and Facilitators of Implementation note that a significant
number of physicians currently involved with treatment programs are not prescribing
buprenorphine. 144 According to them, of those with physician access, forty-nine percent
among private sector programs and sixty-seven percent among public programs did
not prescribe buprenorphine. 145 Additionally, the authors note that the public knows
very little about buprenorphine and other substance use disorder medications. 146 They
hypothesize that if more information was given to the public regarding buprenorphine,
its demand would also increase, thus increasing buprenorphine's availability at public
treatment centers. 147
As mainstream facilities, such as Massachusetts General Hospital, Johns Hopkins,
and Yale New Haven Hospital, 148 start implementing MAT, other hospitals will likely
follow. 149 Because of the prestige of these hospitals, patients, the general public, and
other hospitals are likely to learn about the procedures and practices these facilities
implement. 150 As more hospitals and facilities integrate and implement these new
procedures that larger hospitals have had success with, the standards of communities
across the country will begin to change. 151 The pressure to follow community standards
and the demand for optimal treatment will make it increasingly difficult for facilities to
continue to promote outdated models of treatment.

143
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D. Unfair Business Practices and False Advertising by OUD Treatment Facilities

Unfair business practices used by OUD treatment facilities also contribute to the
treatment gap. 152 There are many documented accusations alleging that OUD treatment
facilities make false claims about their services. 153 Since the FTC has the authority to
prohibit "unfair or deceptive acts or practices," it also has a responsibility to protect
patients from unfair business practices that jeopardize public health. 154 The agency has
already taken action by issuing warning letters to multiple marketers and distributors
who were making false claims about their opioid cessation products. 155 Additionally, the
FTC has worked with SAMHSA to better inform patients who were misguided by false
claims about MAT, 156and the agency provides other resources to help those in need get
the "right" help for addiction and withdrawal. 157
States also have the power to regulate physician advertising that is "false, fraudulent,
deceptive ... misleading," or that "tends to injure the public by lowering or demoralizing
professional standards." 158 Amid the current opioid epidemic, states have a legitimate
interest in promoting the public health and safety of their residents; thus, states can
regulate misleading medical advertising to protect their residents from suffering health
consequences as a result of such advertisements. 159
Similarly, medical associations play a role in ensuring that physicians do not mislead or
deceive patients. The American Medical Association (AMA) provides ethical standards
for physician advertising and states that advertising should be "explicitly and implicitly
truthful and not misleading." 16 Further, the American Osteopathic Association warns
against deceptive statements that are "likely to lead a patient to a misinformed choice

°
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See e.g., Andersen, supra note 12 (reporting that certain treatment facilities claim to treat OUD
addiction without the use of MAT prescriptions).
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and unjustified expectations." 161 OUD patients are accustomed to being beaten down,
and they may be desperate for any type of treatment, making them more vulnerable and
susceptible to misleading advertisements or statements. 162 Therefore, OUD providers
should exercise extra care when making statements or advertising treatment outcomes,
and should be held accountable for the impacts of such statements.
Similarly, medical boards should ensure that providers are informing their patients of
all available treatments, especially those with lifesaving potential. In its Model Policy
for Opioid Treatment, the Federation of State Medical Boards recognized that treatment
with medication should be considered for every OUD patient. 163 Because of the current
treatment gap and the projected increase in deaths from OUD, there is a need for
informed consent that takes the dynamics of an OUD patient into consideration. 164

III. BEST PRACTICES FOR OBTAINING INFORMED CONSENT
FROM OUD PATIENTS
As standards for informed consent and the physician-patient relationship have evolved,
the current OUD treatment dynamic clearly demonstrates the ongoing conflict between
physician paternalism and patient autonomy. 165 The treatment of OUD patients with
B-MAT represents a unique test case for informed consent because of the potential
therapeutic value it may bring to a patient group that has historically been discriminated
against. 166 In this setting, a mutual provider-patient decision, which once seemed
inconceivable, may now be a possible end goal of the use of informed consent to treat
the OUD patient. 167
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outcomes research in this area helps address the historic dilemma of balancing patient autonomy
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Because of the life-and-death ramifications of the current treatment environment, 168 a
clear definition of informed consent is important for the development of the providerOUD patient relationship. Perhaps a tailored definition would later become applicable to
other areas of medicine, but as Jay Katz has suggested, informed consent could contain
different specifications for different categories of cases. 169
A. Scope and Timing

These proposed best practices should be implemented whenever a patient enters care
for OUD. Anytime that a prospective OUD patient seeks advice or treatment from a
medical provider, and the provider in turn agrees to render such advice or treatment,
the provider-ODD patient relationship is created. 170 With the existence of such a
relationship, informed consent for the provider-ODD patient relationship is applicable.
The scope of application for these best practices should include, but is not limited to,
the four points where OUD patients typically enter care: primary care providers (such as
family practice providers, internists, and gynecologists); 171 behavioral health facilities
(such as Universal Health Services ("UHS") and mental health units within general
hospitals); 172 commercial addiction treatment centers (such as Passages Malibu); 173 and
emergency rooms and urgent care centers. 174
B. The Treatment Agreement Requirement

At the outset of the provider-ODD patient relationship, the OUD patient should receive
a written contract ("treatment agreement") that outlines the available treatments
for OUD and clarifies the patient's right to be informed about each of the available
treatments before deciding whether to be treated. 175 Contracts are not a foreign concept
in the treatment of OUD. 176 Unfortunately, OUD patients typically do not have the

REV.

137, 138 (1977).

168

See
Chen, supra note 19 (concluding that m1der the status quo, the munber of opioid
overdose deaths is projected to continue to increase).
169

See Katz, supra note 167, at 173.

171
Primary Care, AM. AcAD. FAM. PHYSICIANS, https://v1rww.aafp.org/about/policies/all/primarycare.html
visited Sept 16, 2019).
172
See
Behavioral Health, UNIVERSAL HEALTH SERV., https://wwvv.uhsinc.com/about-uhs/
behavioral-health (last visited Sept 16, 2019) (providing an overview of universal health services).
173

174

PAS SAGES MALIBU, https://passagesmalibu.com/philosophy/the-four-causes-ofvisited Nov. 2, 2019).

supra note 149.

175

See TIP 63:
Use Disorder Part 5: Resources Related to Medications
Use
Healthcare and Addiction
Patients, and
Families, SAMSHA, 52-53,
The first
two statements in the
treatment agreement ensure that the risks and benefits of alternate
treatments are explained to the
Id.

47
Bupren01phine Medication-Assisted Treatment: J7ze Role efInformed Consent

opportunity to analyze treatment options at the outset, but instead receive a written
contract explaining potential side effects of the medication only after choosing to pursue
B-MAT. 177 Use of a contract at the formation of the provider-ODD patient relationship
narrows the treatment gap by informing patients of all alternative options for OUD
treatment and places the patient in the position to make an informed decision.
In the same way that patients are informed about the risk of death from mixing
buprenorphine with benzodiazepines, the need for additional counseling, and the lack of
a fixed time for the completion of treatment, they should be made aware of the potential
positive outcomes of treatment with buprenorphine. 178 This disclosure should be made
at the formation of the relationship, simultaneously with the disclosure of potential
outcomes of alternative treatment methods. 179 The distribution and execution of a
treatment agreement at the beginning of the relationship allows the patient to see the
"big picture" and to choose a path based on his own personal preferences and needs. 180
Before deciding on a treatment method, the patient should sign the treatment agreement,
which should state that the provider has informed her of the associated risks and possible
alternative treatment options. 181 The treatment agreement should specifically mention
those alternative options and include a description of the available outcome-based
research and government funded resources. 182
C. Methods of Informing Patients of Available Treatment Alternatives

The provider should disclose "medically reasonable alternative" treatments 183 by either
discussing the specific results of outcome-based research and the government funded
resources that are available, or providing those materials for the patient to read on his
own. 184 If the provider chooses to provide the materials to the patient, the provider should
offer to discuss any questions that the patient has about the material. 185 This approach
also allows the patient an opportunity to reflect and make an informed decision. 186
Providers should be aware of potential litigation that they could be subject to if they
fail to inform patients of medication-assisted treatment options. 187 Although settled
outside of court, Osheroffv. Chestnut Lodge, 188 a case in which a provider relied solely

177

Id

178

Jd

180

See
ld

text
181

"'''wn111v

on'''""'nl supra note 176.

182
183

Matthies v. Mastromonaco, 733 A2d 456, 457, 457 (N.J 1999).

184

71P 63:

185

Id

Use Disorder Part 2: /iaare,ssuz17

18.

186
187

Inc .. 490 A2d 720

App. 1985).

188

48
Health Law & Policy Brief• rolume 14, Issue 1 •Winter 2020

on psychotherapy in treating a patient suffering from depression, invited an influx
of malpractice claims on the basis of providing treatment without medication when
medication was available. 189 Treatment facilities should ensure that providers inform
patients about available medications even if the facility does not offer medicationassisted treatment. Providers should be ready to inform a patient when the patient can
receive medication-assisted treatment and of alternate locations that offer MAT.
D. The Decision-Making Process
i. The Patient-Centered Approach

A "patient-centered approach," in which the patient is an active participant, is critical
to the provider-ODD patient relationship. 190 While providers often adopt a paternalistic
approach with OUD patients, due to preconceived notions that the patient has a history
of poor judgement, the best treatment for a patient requires respecting the patient's
autonomy and freedom by allowing the patient to choose from treatment options as
shown through the tenets of motivational interviewing. 191 A patient with a broken leg,
for example, may not need to feel central in his treatment decision-making process%he
would just prefer the best available treatment. However, with the unique treatment of
OUD, the patient-centered approach may be instrumental. Under this approach, "the
physician tries to enter the patient's world, to see the illness through the patient's eyes." 192
Physicians should adopt motivational interviewing techniques to help facilitate the
use of informed consent. Through motivational interviewing, an empathetic, "clientcentered counseling style for eliciting behavior change," patients play an active role in
their healing. 193 One of the basic principles of motivational interviewing is acceptance,
which involves "honoring and respecting each person's autonomy, their irrevocable right
and capacity of self-direction." 194 Providers who incorporate motivational interviewing
into their practice should inform the patient of the available treatment options, place the
patient in the decision-making position, and listen to and empathize with him so that he
has the best chance to get the most effective treatment.
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ii. Elimination ofBias

What a provider believes is the best treatment method should be irrelevant to the
determination of which alternatives should be disclosed. The provider should, in
an unbiased fashion, discuss treatment alternatives based on available research. 195
Informed consent has the potential to transform the doctor-OUD patient relationship
because of the therapeutic value that patients may receive from being closely involved
in their own decision-making. 196 Informed consent "forces the therapist to examine his
biases in regard to valuing his system over other available systems," which causes the
therapist to "join the patient in the major therapeutic task of searching out distortions and
misperceptions." 197 This "mutual participation" has been shown to curb the tendency
toward a "one-size-fits-all treatment." 198
iii. Providers Must Offer Advice, Not Make the Patients Decision

The provider must use his knowledge of the patient's situation to assist the patient in
making an informed decision, but the provider should be careful not to make the choice
for the patient. 199 Through motivational interviewing and a strong OUD providerpatient relationship, the provider learns information unique to the patient. 200 Using
this information, the provider can advise the patient without steering him or effectively
making a decision for him. 201 The provider is in the best position to weigh the risks and
benefits because of the provider's knowledge about the patient's situation. 202
iv. No Therapeutic Privilege Not to Disclose Alternative Treatments

The "therapeutic privilege not to disclose" 203 should not be used with the treatment of
OUD patients because the disclosure of options and the patient decision are significant
Use Disorder Part 3:
Use
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components of a recognized treatment method (e.g. motivational interviewing) for the
OUD patient. 204 Additionally, unlike many illnesses, treatment information is readily
available in patient-readable formats through sources such as the HHS and SAMHSA
(e.g., Treatment Improvement Protocol 63 ("TIP 63"), a document that reviews the use
of FDA approved medications used to treat opioid use disorder). 205 When a potentially
lifesaving decision is at hand, the importance of the decision likely outweighs any reason
to forego full discussion of alternative treatments.

v. Mutual Decision-Making and Participation
The struggle between autonomy and paternalism should be met with mutual decisionmaking, which may not be possible in some areas ofmedicine. 206 In the OUD context,
research provides a clear picture of available alternatives, and a doctor should effectively
communicate those alternatives. 207 Providers should build an environment in which true
decision-making can occur and the doctor's expertise is valued and weighed, but the
patient holds the ultimate decision-making authority.
Ideally, the provider and patient assess the likelihood of success together and mutually
decide the best course oftreatment. 208 Katz identified several factors as impediments to
a patient's self-determination, two of which include the doctor's valuable time and the
patient's limited medical knowledge. 209 These two problems can be alleviated through
the distribution of materials that are easy to understand that the patient can read on his
own time.
Instead ofusing short-term objective management, the provider-0 UD patient relationship
requires communication of the patient's feelings and a discussion of his triggers so
that the physician can better understand the patient's motivations for treatment. 210 To
facilitate the formation of a trusting provider-patient relationship, a provider should,
when possible, learn about the patient's background to offer optimal advice about a full
treatment plan. 211 A comprehensive plan may incorporate recommendations on how to
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avoid triggering situations, or advice to seek outside counseling when doing so would
benefit the patient. 212
A joint provider-patient decision is especially important in the treatment of the ODD
patient because of ODD's classification as a chronic condition. 213 The patient's active
participation in his own care is essential for successful treatment, as daily medicines
and frequent counseling are usually required. 214 This unique provider-ODD patient
relationship contrasts significantly with the short-term management of such emergency
events as cardiac arrest or trauma. 215
vi. Honest Communication
A strong provider-ODD patient relationship encourages patients to be honest and
disclose to the physician when they fail to meet the treatment guidelines. The provider
will be in the best position to detect the patient's failure and help the patient take
appropriate steps to move forward with the treatment. 216 Because of the nature of the
relationship, a patient trusts that his provider has his best interests in mind and he feels
more comfortable disclosing sensitive information, even when the information may
elicit negative consequences. 217
vii. "Reasonable Patient" and "Specific Patient" Standards
A provider should tell an ODD patient all information that a reasonable patient would
consider important in making a treatment decision and information that the provider
knows that the specific patient would consider important. 218 However, a patient has the
right to choose any treatment option, including no treatment at all. 219 While it seems that
requiring "truly informative" informed consent closes the treatment gap, a provider's
respect for patient autonomy allows for patients to decide not to accept treatment even
when fully informed. 220
Patients cannot have autonomy when they are uninformed. Katz argues that the
reasonable patient standard may "abrogate the very right at issue in cases of informed
consent," which he alleges is "the right of the individual choice;" however, the reasonable
patient standard is used to convince providers to thoroughly inform patients because
providers are bound to inform patients of all information that a reasonable patient
would find important in making a treatment decision. 221 A reasonable patient likely
finds information about the most successful treatment for a life-threatening condition
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important in making a treatment decision. 222 Further, if a provider has reason to believe
that a specific patient would find the information important in making a decision, the
provider must also inform that patient of such information. 223 This standard forces
providers to think through the eyes of the patient and encourages the provider to develop
an understanding of the patient's perspective.
E. Business Practices, Advertising, and Facility Responsibility

i. Extension ofLiability to Facilities

Informed consent requirements extend to hospitals and treatment centers. 224 To the
extent that false advertising and unfair business practices still exist, providers should
be aware of the role that states, medical associations, and government agencies play
in regulating false or misleading statements about the effectiveness of OUD treatment
methods. 225 Facilities must play an active role in promoting the best treatment options
through the distribution of accurate and non-deceptive materials. 226
ii. Disclosure of Treatments Not Offered at the Facility

As community standards improve, businesses and facilities should implement the
treatments that have proved most effective through outcomes research. To the extent
that the facility is unable to implement those treatments, the providers at the facility are
obligated to inform patients of the effectiveness of the alternate treatments not offered at
that facility and allow and encourage the patient to consider the possibility of receiving
that treatment elsewhere. 227
iii. Scope ofApplication

Informed consent should apply to non-physician providers in the OUD setting. It is
understood that OUD treatment involves not only medication, but also some sort of
counseling in many cases. 228 Further, for prescribers to receive authorization they must
attest that they have access to counseling resources. 229 Often, counseling resources will
occur through a prescriber's referral, and such resources will be provided by outside
psychologists, social workers, or other providers. 230 Because of the important role of
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non-physician providers in OUD treatment, it is critical that these providers are aware
of and prepared to support a patient's decision to receive medication-assisted treatment.
To be able to inform patients in an honest and ethical manner, these non-physician
providers need to be informed of treatments and prepared to confront their own biases
so that they do not undermine medication treatment. Across the nation there are various
state laws that discuss informed consent standards for psychologists, social workers, and
other providers, so informed consent is not limited to physicians. 231

CONCLUSION
The unfortunate reality of the current status of B-MAT treatment is that scientific
and medical research is seemingly ignored because of the existing bias against OUD
patients. 232 The benefits of informed consent could be portrayed through B-MAT
treatment if the informed consent requirement is consistently enforced. 233 While
new challenges regarding B-MAT may arise in the future, or a new treatment option
may become available, the use and enforcement of informed consent is crucial to the
narrowing and elimination of the treatment gap.
Because of the unique factors related to the OUD epidemic, specialized informed consent
requirements should be implemented for the provider-ODD patient relationship. Before
addressing regulations at the top level or deciding which treatment program is optimal,
it is imperative that OUD patients are placed in the decision-making position and fully
informed of all available treatments. As these patients learn about the comparative
success of B-MAT, the disparity of the current treatment gap will become apparent.
Legislators will be compelled to act and facilities will be forced to confront the researchbacked best practices and adapt to the demand for implementation of such practices.
By trusting OUD patients to make decisions and to control their own treatments and
futures, a strong provider-patient relationship will overcome the biases of the community
and penetrate all models of OUD treatment. The past moral choices of a patient should
have no bearing on the duties of a provider treating that patient. Whenever a providerOUD patient relationship is formed, the OUD patient should be informed of the available
treatment options%not guilted into choosing an outdated, unsuccessful program that
offers little chance of success. 234
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While this Article specifically examines the important role of informed consent in the
doctor-OUD patient relationship, the principles of patient autonomy apply broadly to
patient care. Healthcare is a dynamic field. 235 Diseases and their prevalence change
with time as available information and treatments evolve. 236 A strong provider-patient
relationship is an important foundation in any patient care.
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